Homepage How it works Sample report Get your report On your side Free checker
Free checker Get your report · £49 →
Our position
On your
side.
The supplement industry earns money when you are confused. We built Distil to do something different: to inform you: honestly, specifically, in your interests, about something that can genuinely help. Not to exploit the fact that you want to feel better.
This page explains the choices we make that are against our commercial interests and in yours. They are not accidental. They are what makes the report worth having.

Most supplement guides are, at their core, sales funnels. The recommendations exist because someone earns a margin on them. The advice is generic because personalisation is expensive and takes effort. The evidence standards are vague because specificity creates accountability, and accountability is inconvenient when you want to recommend everything.

The result is an industry that profits from confusion. The more you don't know, the easier it is to sell you something. The harder it is to verify a claim, the more freely it can be made. This is not a description of the worst actors. It describes the structure of the market.

We built Distil because we found this genuinely frustrating. We could not find a place that would tell us, honestly, what was worth taking for a specific person with a specific profile, without trying to sell us something on the back of it. So we built the thing we wished existed.

"The goal is to inform you over something that can genuinely help you. Not to exploit the fact that you want to feel better."

The report we generate is designed to inform, not to maximise spend. That produces some concrete choices: in how we source, what we include, what we tell you to avoid, and what we tell you not to buy. Each of those choices is documented below. Not as brand positioning. As a record of what we actually do.

Sourcing integrity

Every compound card tells you what to avoid on labels

Most supplement guides tell you what to take. Ours also tells you what not to buy, and why, for every compound in your stack.

The supplement market is full of inferior forms: low-absorption minerals, outdated vitamin isomers, extracts that differ from what was used in clinical trials. A guide that tells you to take Magnesium without specifying the form is sending you toward a product that may deliver under 4% of its stated dose. That is not helpful. It is closer to the opposite.

Every compound card in your report includes a "What to avoid" section with specific, named reasons. It also includes exact UK search terms, not to direct you to a preferred retailer, but so you can find the right product from anyone.

We have no affiliate links. We earn nothing from what you buy. The search terms exist entirely to help you find a product that matches the clinical form, dose, and specification in your report.

From the report: What to avoid
Magnesium oxide
Under 4% elemental absorption. The most common form on UK shelves. Provides almost no functional magnesium at the stated dose.
Ergocalciferol (D2)
Inferior conversion to active D3. Clinically outperformed by cholecalciferol across all outcomes. Still widely sold as Vitamin D.
K2 as MK-4
Much shorter half-life than MK-7. Requires multiple daily doses to maintain effect. MK-7 achieves the same outcome with once-daily dosing.
Generic ashwagandha
root powder
Not clinically equivalent to KSM-66. Human RCTs use the extract. Generic powder is not the tested form and cannot be assumed to produce the same outcomes.
Products without
elemental weight stated
Total capsule weight is not elemental magnesium. Any product that does not state elemental weight separately cannot be reliably dosed.
No affiliate links · No preferred retailer · Search terms are for your benefit, not ours
Transparency of reasoning

We show you what was considered and not recommended

Most supplement guides show you their inclusions. Ours shows you its exclusions too: which compounds were evaluated, scored, and placed below the threshold for this profile, and why.

This matters for two reasons. First, it lets you verify the reasoning. If a compound you expected to see is absent, the report explains its absence rather than leaving you to wonder whether it was overlooked. Second, it demonstrates that the selection process is real. A guide that recommends everything has not selected anything.

For every compound that was considered but not included, the report documents why: insufficient evidence for this profile, superseded by a better-evidenced alternative, deferred because it depends on the foundation being established first, or excluded for a safety reason. Deferred compounds are explicitly revisited at the 12-week reassessment point.

Showing your reasoning is how you earn trust. Hiding it is how you sell more.

From the report: Compound considered, not included
Valerian Root
Deferred: not included at this stage
Why considered
Relevant for sleep onset. Valerian has documented GABA-A agonist activity and a reasonable body of human trial data for sleep latency reduction. Sleep onset is a stated goal for this profile.
Why not included
Insufficient extract standardisation in commercially available products makes consistent dosing difficult. The sleep onset goal is addressed by L-Theanine and Glycine with better evidence and more reliable sourcing. Valerian is not necessary at this stage.
Reassessment
Review at 12-week checkpoint. If L-Theanine and Glycine have not adequately improved sleep onset, Valerian becomes relevant as a next layer. Flagged for that conversation.
Blood work

We tell you which tests to get before you spend

Some compounds are only worth taking if a deficiency or imbalance is confirmed. Others should be calibrated against a baseline before you start. Your report includes a blood work section specifying exactly which tests matter for your profile, why, and what result you are aiming for.

Sometimes that information changes what you need. Ferritin below 50 µg/L is associated with cognitive symptoms and fatigue even when haemoglobin is within the normal laboratory range, and most GPs do not routinely test for it, or explain this distinction. If your ferritin is low, that is a different intervention than if it is adequate. We include this because it is the right information to give, not because it maximises your stack size.

In some cases, the blood test result means you need fewer compounds than the report initially recommended. We include the blood work section anyway. The goal is accurate information, not maximum spend.

From the report: Blood work recommended
Vitamin D (25-OH)
No recent test available. Limited sun exposure and office-based week make deficiency likely. Target: 100–150 nmol/L. Test before starting or at the 12-week mark to confirm whether the selected dose is achieving repletion. Dose can be adjusted upward if needed.
Ferritin
Persistent fatigue and mid-afternoon energy drop can reflect low ferritin even when haemoglobin is within the normal laboratory range. Ferritin below 50 µg/L is associated with cognitive symptoms and reduced energy. Iron supplementation is not included in this stack without confirmed deficiency; testing is the only way to rule this out.
Lipid panel
First-degree relative diagnosed with cardiovascular disease. A baseline lipid panel at next GP visit is recommended. Results will calibrate Omega-3 and CoQ10 dosing going forward.
Testosterone (total + free)
Optional but useful baseline for a 34-year-old male beginning Ashwagandha. Provides a pre-supplementation figure for comparison at 12 weeks.
Inter-compound coordination

The stack is coordinated, not assembled

A list of compounds is not a stack. A stack is a set of compounds whose doses, forms, and timing have been adjusted for what every other compound in the set is doing.

Magnesium Glycinate at 400mg elemental delivers approximately 2.4g of glycine as a co-amino acid nightly. A naive glycine recommendation would be 3–5g before bed for sleep. But when Magnesium Glycinate is already in the stack, the standalone Glycine dose is set at 3g, because the total cross-compound glycine is tracked and the combined 5.4g is the effective dose, not 3g and 5g independently.

Similarly, Zinc is placed at lunch, not because lunch is when zinc is conventionally taken, but because zinc and magnesium compete for the same intestinal transporter. Taking them at the same meal reduces the absorption of both. Separating them by meal slot is a coordination decision, not a timing preference.

Phosphatidylserine is placed in the morning specifically because this profile has a sleep goal. Taken in the evening, it can impair sleep onset in some individuals. The compound is beneficial; the timing is where the personalisation happens.

This coordination runs through the entire stack. Nothing in your report is a generic recommendation pasted onto your profile. Every dose, every timing, every form has been set in the context of everything else.

Inter-compound adjustments: from the report
Magnesium Glycinate
Delivers ~2.4g glycine nightly as co-amino acid
Glycine: 3g (not 5g)
Combined total: 5.4g. Dose set to account for co-delivery
Magnesium Glycinate
Before bed: GABA-A + NMDA modulation
Zinc: placed at lunch
Avoids transporter competition. Separating by meal slot preserves absorption of both
Sleep onset: stated goal
Profile shows difficulty falling asleep
Phosphatidylserine: morning only
Evening dosing impairs sleep onset. Moved to morning despite cognitive goal
Rhodiola Rosea
Stimulating adaptogen with energy goal
Before or with breakfast only
Clinical literature: afternoon or evening dosing consistently disrupts sleep onset
Sleep analysis

Sleep is not one problem

The questionnaire distinguishes between two distinct sleep problems: difficulty falling asleep (onset) and waking during the night (maintenance). These are different physiological problems, addressed by different mechanisms, requiring different compounds, often at different times of night.

A recommendation of "take something to help with sleep" that does not make this distinction may address one problem while missing the other entirely. Worse, a compound that helps onset can sometimes impair maintenance, and vice versa. Getting this wrong is not a minor issue.

Your report identifies which subtype or combination applies to your profile and selects compounds specifically for that mechanism. If you have an onset problem, the primary targeted compound is L-Theanine, which promotes alpha-wave activity and reduces sleep latency. If maintenance is the issue, Ashwagandha, timed to the evening, addresses HPA axis dysregulation and the night-waking pattern that often follows elevated evening cortisol.

The same compound at the wrong time, or the wrong compound for the wrong subtype, is not personalisation. It is a guess with good packaging.

Subtype 01
Onset difficulty
L-Theanine Alpha-wave promotion · sleep latency
Glycine Core body temp reduction · NMDA
Apigenin GABA-A binding · sleep depth
Subtype 02
Maintenance / night waking
Ashwagandha HPA axis · evening cortisol
Magnesium Glycinate GABA-A + NMDA · cortisol
Glycine Deep sleep architecture
Timing matters as much as compound selection. Ashwagandha is placed in the evening specifically to lower cortisol ahead of the maintenance window. L-Theanine is timed 30–45 minutes before sleep to address the onset window. Both are precision decisions, not defaults.
Dietary baseline

Sometimes the answer is food, not a capsule

Before any compound is recommended, the report analyses your dietary baseline across every nutritional dimension relevant to your goals. This is not a formality. It changes what gets recommended.

If your dietary calcium intake from dairy is adequate, a calcium supplement is not added to your stack, even if it might theoretically provide some benefit. If your choline intake from eggs is sufficient for your age and goals, standalone choline is not recommended. If your B12 absorption looks fine from your omnivorous diet, a standalone B12 is not included on top of the B Complex.

The dietary baseline also informs dosing. If you eat oily fish once a week, your Omega-3 dose accounts for that contribution, rather than treating you as if your dietary EPA+DHA intake is zero. If you are a moderate alcohol drinker, that affects magnesium demand. If you skip breakfast, that changes how fat-soluble compounds are timed.

The goal of this analysis is to recommend supplements where they genuinely add to your diet, not where your diet already covers the need. A shorter stack that addresses real gaps is more useful, and more honest, than a longer one that pads out something already adequate.

19
Nutritional dimensions
analysed per profile
Vitamin D
Supplementation clearly indicated: office-based, UK latitude
Calcium
Adequate from daily dairy: not supplemented
Choline
4–5 eggs per week provides adequate intake: not supplemented
Vitamin B12
Omnivorous diet with regular eggs + dairy: covered by B Complex only
Omega-3
Oily fish once per week contributes 0.5–0.7g EPA+DHA, below therapeutic threshold: supplemented
Ferritin / iron
Not supplemented without confirmed deficiency: blood test flagged instead
Meal timing
Breakfast-skipping identified as root cause of afternoon slump: dietary note added alongside compound recommendations
"On your side" means we will always tell you what the evidence does not support as clearly as what it does.

We will tell you when food is a better answer than a capsule. We will show you what was considered and rejected, and why. We will give you exact search terms so you can buy from any retailer. We will flag the blood tests that matter before you spend, even if the results mean you need fewer things than you thought.

None of that serves our commercial interests. All of it serves yours. That is what the report is for.

Get your report